Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 4Neoplasms 2Multiple Myeloma 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Testicular Neoplasms 1Testicular Germ Cell Tumor 1Seminoma 1Prostate Cancer Metastatic 1Ovarian Neoplasms 1Neutropenia 1Lymphoma, B-Cell 1Hodgkin Disease 1Endodermal Sinus Tumor 1Central Nervous System Neoplasms 1Castrate Resistant Prostate Cancer 1

Interventions

Rituximab 112Cyclophosphamide 103fludarabine 61Doxorubicin 33Vincristine 31Etoposide 31Prednisone 30Lenalidomide 24ibrutinib 22fludarabine phosphate 21Immunotherapy, Adoptive 19Bendamustine Hydrochloride 19obinutuzumab 18Cytarabine 18pembrolizumab 16Magnetic Resonance Spectroscopy 16Bortezomib 14Specimen Handling 13Dexamethasone 13polatuzumab vedotin 12CT-P10 12venetoclax 11Gemcitabine 11Carboplatin 11pirtobrutinib 10glofitamab 10zanubrutinib 9Nivolumab 9Mycophenolic Acid 9Melphalan 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, B-Cell × Lenograstim × Clear all
NCT00379574 2013-03-15

Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL

Asan Medical Center

Phase 1/2 Completed
49 enrolled 8 charts
Lymphoid

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡